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Abstract 
Purpose: To enhance the solubility and dissolution characteristics of ketoprofen using various 
crystallization techniques.  
Methods: Ketoprofen crystals were prepared by various crystallization technique including spherical 
agglomeration (SA), spray drying (SD), freeze drying (FD) and super cooling (SC). The crystallization 
medium used for all the techniques consisted of water and chloroform. Residual solvents in the crystals 
were determined and the crystals were characterized by DSC, FT-IR, XRD and SEM. Both solubility and 
dissolution behavior studies were carried out. The physical stability of the crystals were also evaluated 
after storage over a period of time. 
Results: Residual IPA and chloroform in the crystals ranged from 4.10 - 5.70 and 1.84 - 2.57 ppm, 
respectively, which are well below their toxic limits. The crystals obtained exhibited lower crystallinity 
than the original drug. The solubility of FD crystals in water increased almost fivefold to 0.0926 mg/ml 
compared with that of the drug (0.0172 mg/ml), while the dissolution rates of the developed crystals 
were than that of the original crystals. For example, FD crystals demonstrated the highest dissolution 
(99.9 %) compared with original crystals (64.3 %). In the stability test, the dissolution profiles of the 
developed crystals remained largely unchanged over the period of the stability study.  
Conclusion: The re-crystallization techniques used in this study can be applied to obtain modified 
ketoprofen for formulation of tablets of the drug with improved drug dissolution.  
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Ketoprofen is a non-steroidal anti-inflammatory 
drug, scarcely soluble in water, and is widely 
used as analgesic as well as for the treatment of 
acute and long-term rheumatoid arthritis and 
osteoarthritis. Its short elimination half-life and 
adverse effects, such as gastrointestinal mucosa 
ulceration, restrict its oral use [1-2]. Due to the 
high barrier properties of skin, the need to use 
safe and effective enhancers for improving 
transdermal absorption of drugs is well 
recognized [3-6]. 
 
Formulation and manufacture of solid oral 
dosage forms, tablets in particular, have 
undergone rapid change over several decades. 
One of such changes is direct compression. 
Direct compression is economical, facilitates 
processing without the need of moisture and 
heat, and involves a small number of processing 
steps. In direct tableting, it is necessary to 
increase flowability and compressibility of the 
bulk powder in order to retain a steady supply of 
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powder mixture to the die cavity and impart 
sufficient mechanical strength to the compacted 
tablets [7, 8].  
 
In addition to increasing efficiency of the 
manufacturing process it is also important to 
increase the bioavailability of the drug by 
improving the solubility of the bulk drug powder. 
Freeze drying is one of such techniques to 
improve the micromeritic properties and 
dissolution of drugs. Currently, several 
solubilization techniques have been reported to 
enhance the solubility of poorly water soluble 
drugs; however, few literature are available on 
the enhancement of the solubility and dissolution 
of ketoprofen, and these include formation of 
inclusion complexes with cyclodextrin [9] and 
skimmed milk [10]. To enhance the dissolution 
rate and bioavailability of ketoprofen, a novel dry 
elixir dosage form was proposed [11]. The 
formation of ketoprofen solid dispersion and 
ketoprofen-dextran ester prodrug has also been 
reported to improve ketoprofen solubility and 
dissolution [12,13]. The mechanism of increased 
dissolution rate of drugs by solid dispersion 
crystallization technique has been attributed to a 
number of factors such as drug amorphization, 
increased drug solubility, reduction in particle 
size, a higher degree of surface area and 
porosity [14-17]. 
 
Therefore, the objective of the present study was 
to prepare different crystals of ketoprofen by 
various crystallization techniques and to evaluate 




Ketoprofen was obtained as a gift from Micro 
Lab, Bangalore, India. All chemicals and buffers 
used were of analytical grade (Merck Pvt Ltd. 
Mumbai)  
 
Preparation of ketoprofen spherical 
agglomerates (SA) 
 
Ketoprofen (4 g) was dissolved in 25 ml of 
isopropyl alcohol (IPA) at 45 0C until a clear 
solution was obtained. The drug solution was 
poured quickly into 60 ml of water maintained at 
20 0C, under continuous stirring at 500 rpm with 
a propeller. When fine crystals of ketoprofen 
begin to precipitate (5 - 10 min later), 10 ml of 
chloroform (bridging liquid) was added. After 10 
min of stirring, 5 ml of chloroform was again 
added. The temperature was reduced to 5 0C, 
and after about 1 h stirring, the spherical 
agglomerates formed were separated from the 
solution by filtration, dried at 45 0C for 12 h and 
kept in a desiccator room temperature until used 
in further experiments.  
 
Preparation of spray-dried ketoprofen 
crystals (SD) 
 
Ketoprofen (4 g) was dissolved in 25 ml of IPA at 
45 0C until a clear solution was obtained. The 
drug solution was poured into chloroform (15 ml) 
at room temperature. The resulting solution was 
spray dried (Mini Spray Dryer LSD-48, Jay 
Instrument & Systems Pvt, Ltd, Mumbai) at a 
feed rate of  10 %, -65 MM WC vacuum system, 
atomization pressure rate of 1 kg/cm2 , aspirator 
level of 35 %, inlet temperature of 85±2 °C and 
outlet temperature of 40 ± 1 °C. The crystals 
formed were separated using a cyclone 
separator, collected and stored in a desiccator at 
ambient temperature until use. In spray dried 
water is used as ketoprofen melting point is lower 
than the water. 
 
Preparation of freeze-dried ketoprofen 
crystals (FD) 
 
Ketoprofen (4 g) was dissolved in 25 ml of IPA at 
45 0C until a clear solution was obtained. The 
drug solution was poured into a solvent system 
consisting of water (60 ml) and chloroform (15ml) 
at room temperature. The resulting solution was 
transferred to a 100 ml glass bottle and placed in 
an ultra-low temperature freezer at -40 0C for 24 
h. The frozen sample was then placed in a 
lyophilizer (IISHIN Lab Co Ltd, Korea) for 72 h at 
a condenser temperature of -40 0C and a 
pressure of 7×10-2 mbar, followed by secondary 
drying at 25 0C for 24 h. The resulting crystals 
were kept in a desiccator at room temperature 
pending further tests. 
 
Preparation of super-cooled ketoprofen 
crystals (SC) 
 
Super-cooled crystals of ketoprofen were 
prepared by melting the drug (5 g) at 95 ± 5 °C 
on a heating mantle. The resulting solid crystals 
were kept at room temperature for 5 min, shifted 
to a freezer for 1 h and then kept in a desiccator 
at room temperature until further use. 
 
Preparation of recrystallized ketoprofen (RS) 
 
Ketoprofen (4 g) was dissolved in 25 ml of IPA at 
45 0C and 15 ml of chloroform added. The drug 
solution was poured quickly into 60 ml of water at 
20 0C with occasional stirring. The crystals of 
ketoprofen formed were collected by filtration and 
dried at 45 0C for 12 h.    
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Determination of residual solvents in crystals  
 
Gas chromatography (GC) was carried out on a 
computerized GC system (model 2014, 
Shimadzu Technologies, Japan) coupled with a 
split/splitless injector, operated in a split-mode 
and FID. Rtx-5 capillary column (cross bond 
5%di-phenyl/95%di-methyl-polysiloxane) with a 
length of 30 meters coil and an internal diameter 
of 0.25 mm was used for the studies. 
 
Differential scanning calorimetry (DSC) 
 
A DSC study was carried out to detect possible 
polymorphic transition during the crystallization 
process. DSC measurements were performed on 
a DSC DuPont 9900, differential scanning 
calorimeter with a thermal analyzer.  
 
Fourier transform infrared (FTIR) 
spectroscopy 
 
FTIR spectral measurements were taken at 
ambient temperature (Shimadzu, model 8033, 
USA). About 2 mg of the pure drug, as well as 
recrystallized crystals and spherical 
agglomerates were tested separately. Pure drug 
and all the prepared crystals  In each case, the 
sample was dispersed in potassium bromide 
(KBr) powder and compressed to pellets at a 
pressure of 6000 kg/cm2.  
 
X-ray diffraction analysis 
 
X-ray powder diffraction patterns were obtained 
to detect possible polymorphic transitions during 
the crystallization process. The test was carried 
out using Rigaku Miniflex II x-ray diffractometer 
with Ni-filtered radiation of wavelength of 1.5406 
Å (Cu Target). The samples were scanned in the 
2θ range of 0 - 50 o. The scanning speed used 
for the recording was 3 o/min at steps of 0.02o.  
 
Scanning electron microscopy (SEM) 
 
Scanning electron microscopic (Joel-LV-5600, 
USA, magnification of 250 x) photographs were 
obtained to determine crystal nature and 
morphology.  
 
Particle size measurement 
 
The particle size of most of the crystal samples 
was determined by microscopy method using a 
calibrated ocular micrometer but the size of the 
spherical agglomerates was determined by 
sieving method and that of the freeze-dried 
crystals by a submicron particle analyzer 
(Zetasizer Nano ZS, Malvern Instruments, UK). 
Particle size distribution of crystals is reported by 
intensity. The measurement was performed at 25 
0C and DTS software (version 4.0) was used to 





The solubility of the ketoprofen crystals in water 
and phosphate buffer (pH 7.4) was determined 
by taking excess quantity of sample and adding 
to screw-capped 50 ml glass vials filled with 
water or phosphate buffer. The vials were 
shaken for 24 h on a mechanical shaker. The 
solution was filtered through Whatman filter 
paper no.1 and the drug concentration was 
determined spectrophotometrically at 260 nm.  
 
Dissolution studies  
 
Dissolution test on the ketoprofen samples was 
carried out using a USP dissolution test 
apparatus XXIV-Type II (Electro Lab Mumbai, 
India). The dissolution medium (900 ml) 
consisted of phosphate buffer (pH 7.4). 
Dissolution sample fluid (10) ml was withdrawn at 
10 min intervals over a period of 1 h. The amount 
of dissolved drug was determined 
spectrophotometrically (model UV 1601A, 
Shimadzu, Japan) at 260 nm.  
 
Determination of physical stability 
 
To determine the physical stability of SA, SD and 
FD, they were placed in a climate chamber set at 
40 0C and 75 % relative humidity (RH). After 90 
days, dissolution test was carried out on the 
stored samples and the data compared with 




Comparison among the prepared crystals and 
the reference (pure ketoprofen) were made by 
Student t-test at 95 % level of confidence using 




A typical spherical crystallization system involves 
a good solvent (such as IPA), a poor solvent 
(such as water) for a drug and a bridging liquid 
(such as chloroform). The selection of these 
solvent depends on the miscibility of the solvents 
and solubility of the drug in individual solvents 
(Fig 1).   
 
Residual solvent  
 
Gas chromatography (GC) results indicate that 
residual solvent was in the range 4.1 - 5.7 and 
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1.84 - 2.57 ppm of IPA and chloroform, 
respectively, in the prepared crystals, was and 
these values are much lower than the toxic levels 
of 400 and 60 ppm, respectively[16,17].  
 
 




The DSC thermograms (Fig 2) show a sharp 
endothermic peak for all the ketoprofen crystals. 
This one step melt is be due to only one crystal 
form (triclinic) of the ketoprofen formed during 
the crystallization process, thus indicating that 
ketoprofen did not undergo any crystal 
modification. The temperature range of the 
endothermic peak for all the ketoprofen crystals 
94 to 96 0C. Melting points show slight variation 
as the nature of the crystals might have been 
affected by the solvent. The melting endotherm 
for pure ketoprofen sample was 96.58° with 
enthalpy of 181.01 J/g [4] whereas in the case of 
freeze dried crystals melting endotherm was 
94.23 °C with decreased enthalpy of 174.31 J/g, 
indicating decreased crystallinity.  
 
The DSC thermogram of the super-cooled 
crystals (SC) of ketoprofen showed a melting 
endotherm at 96.23 °C with an enthalpy of 
178.87 J/g, indicating decreased crystallinity but 
not as much as in other prepared crystals. 
  
 




All the prepared crystals except super-cooled 
crystals (SC) and original ketoprofen exhibited 
general characteristic peaks at 2983 - 2930 cm-1  
(aromatic C-H stretch, carboxylic acid O-H 
stretch), 1695 - 1649 cm-1 (C=O stretch), 1595 
cm-1 (aromatic C=C stretch), 1437 cm-1  (CH-CH 
3 deformation), 2891 cm
-1  ((C-H) stretch plus O-
H deformation), 1690 cm-1  (carboxylic O-H out of 
plane deformation), and 860 - 640 cm-1 (C-H out 
of plane deformation for substituted aromatic) [9].  
 
X-ray diffractory 
X-ray diffraction was used to analyze changes in 
the inner structure of ketoprofen crystal during 
modification into the various crystals. The 
characteristic peak of ketoprofen appeared in the 
2θ range of 0 – 50 0, indicating that the original 
(unprocessed) ketoprofen was a crystalline 
material. All the samples showed similar peak 
positions thus ruling out the formation of 
polymorphs of ketoprofen. However, the relative 
intensities of the peaks varied according to the 
crystal type (Fig 3).  
 
 
Fig 3: X-ray diffraction spectra of ketoprofen 
crystals 
 
Particle size and morphology 
 
SEM (Fig 4) show that the original ketoprofen 
crystals had a size range 6 - 17 µm and were 
irregular in shape. Recrystallization led to 
crystals (RS) with intermediate size (13  -26 µm) 
and rod-like shape. The agglomerates (SA) had 
a rough surface covered with numerous rod-
shaped crystals (350 - 830 µm). The shape of 
spray-dried crystals (SC) was uniform, spherical 
and very small in size (5-10 µm) while the freeze-
dried crystals (FD) appeared as microcrystalline 
particles with a smooth surface and very small 
size (mean particle size, 136.8 nm). Super-
cooled crystals (SC) had an irregular shape and 
rough, hard surface with yellowish color, and a 
size in the range 26-34 µm.   
 
Solubility of ketoprofen 
  
All the prepared crystals showed greater 
solubility than the original drug in water as well 
as in phospate buffer (pH 7.4). FD crystals 
showed the highest solubility (0.0926 mg/ml) and 
was 5-fold more soluble than the original 
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ketoprofen (0.0172 mg/ml) in water and nearly 4-




Fig 4: SEM of various ketoprofen crystals 
 
Dissolution characteristics of ketoprofen  
 
The dissolution profiles of ketoprofen are shown 
in Fig 5. The prepared crystals, except super-
cooled crystals, exhibited higher dissolution rate 
than original ketoprofen. The reason for this 
faster dissolution could be the better wettability of 
the prepared crystals and/or reduction in particle 
size of prepared crystals. The amount of drug 
dissolved in 60 min greatly varied for all the 
crystals.   
 
Figure 5: Dissolution of ketoprofen crystals. 
Key: Original ketoprofen = ◊, RS = ■, SC = ∆, SA 
= ×, SD = ▬, and FD = ○ 
 
Physical stability of ketoprofen 
 
There was no change in ketoprofen release from 
the prepared crystals after 90 days of storage, 





Isopropyl alcohol (IPA) is miscible in any 
proportion with water and chloroform. If the 
ternary diagram is drawn to select a solvent 
composition, chloroform/water mixture is like an 
emulsion in a large area of the diagram. The 
points on the vertex correspond to a pure liquid; 
those on the sides correspond to a mixture of 
only two liquids. Since the presence of three 
liquids is necessary (good solvent, bridging 
solvent and poor solvent) for spherical 
agglomeration, points on the sides of the triangle 
are excluded. As many as 36 points remain for 
experiments. Each triangle in the ternary diagram 
was investigated for crystallization. The optimal 
ratio for spherical agglomeration can be found in 
diagram. The proportion of IPA/water/chloroform 
chosen for the study was the same for all the 
crystallization techniques used. 
 
Recrystallization of ketoprofen was carried to 
elucidate changes induced in the crystal lattice 
ketoprofen by the solvents used. The same 
solvent composition was used for all 
crystallization procedures[15]. Based on the high 
solubility of ketoprofen in IPA (2 g/12.5 ml), high 
viscosity and crystal morphology of the 
regenerated product, IPA is the most suitable 
solvent for the re-crystallization of ketoprofen. 
Consequently, control of residual IPA is required, 
being a toxic organic solvent.  However, since its 
residual concentration in the products below the 
minimum levels, to the re-crystallized products 
should be fit for human consumption [16,17]. 
 
DSC results indicate that the crystallinity 
decreased in all the prepared crystals except 
super-cooled crystals. This suggests that there 
was increased amorphous fraction as a result of 
the preparative processes. Specific changes in 
IR spectra are not very clear, but these could be 
due to variations in the resonance structure, 
rotation of a part of a molecule, certain bonds, 
minor distortion of bond angles, or even the 
presence of solvent of crystallization. Infrared 
spectra of pure Ketoprofen, RS, SA, SD, FD 
crystals showed characteristic peaks in same 
position. It would appear that the super-cooled 
crystals prepared by heating the drug before 
cooling it, has a different crystalline form from 
that in the original sample and in all other 
prepared crystals. The reduced relative 
intensities of all the prepared crystals, compared 
with the original drug can be attributed to the 
markedly different crystal habits of the materials. 
Thus, the relative abundance of the planes 
exposed to the x-ray source would have been 
altered, producing variations in the relative 
intensities of the peak or may be due to 
differences in crystal sizes [10,11]. The original 
drug exhibits its characteristic diffraction peaks at 
various diffraction angles indicating the presence 
of crystallinity. Changes in crystallinity may 
explain the observed enhancement of solubility 
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and dissolution of ketoprofen from the various 
crystal types. 
 
Agglomerates (SA) were formed by coalescence 
of the microcrystalline precipitate formed, The 
spherical shape of the spray-dried crystals 
prevented the crystals from progressing to cake 
formation during storage due to minimal points of 
contact on crystal surface, thereby increasing the 
stability of the preparation,  
 
The enhanced solubility of almost all the 
prepared crystals may be due to their higher 
wettability and/or reduction in particle size. On 
the other hand, the increased solubility of the 
super-cooled crystals may be due the change in 
drug molecules or conversion to other molecules.  
The dissolution behavior of the prepared crystals 
remain unchanged during storage. This implies 
that their residual solvent and crystallinity level 
remained constant during the storage, thus 
indicating that the prepared crystals when 
formulated into dosage forms are likely to retain 




Spherical agglomeration, spray drying and freeze 
drying techniques are suitable methods for 
regenerating ketoprofen, a poorly soluble drug. 
The regenerated crystals, being more soluble 
and with faster dissolution rate, would be 
appropriate for the formulation of ketoprofen 
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